Baruch S. Blumberg Institute Congratulates Michael J. Sofia on Receiving 2016 Lasker-DeBakey Clinical Medical Research Award

The Baruch S. Blumberg Establishment, the examination arm of the Hepatitis B Establishment, is pleased to praise Michael J. Sofia, Ph.D., on getting the 2016 Lasker-DeBakey Clinical Restorative Research Grant for his part in the revelation of the cure for interminable hepatitis C. Sofia is an inhabitant extra teacher at the Baruch S. Blumberg Foundation and Boss Logical Officer of Arbutus Biopharma, which now is concentrating on building up a cure for hepatitis B.

The Lasker Grants rank among the world’s most commended logical respects for biomedical research and many think of them as America’s Nobel Prizes; truth be told, 87 past Lasker awardees have gone ahead to get the Nobel Prize.

Sofia will get the 2016 Lasker-DeBakey Grant on Sept. 23 alongside Charles Rice, Ph.D., of Rockefeller College and Ralf Bartenschlager, Ph.D., of Heidelberg College, who were perceived for their work in creating frameworks fundamental to hepatitis C inquire about, which Sofia utilized as a part of building up the medication, sofosbuvir. His work on sofosbuvir was performed while he was at the Princeton-N.J.- based organization Pharmasset, which later was obtained by Gilead Sciences.

“The disclosure of sofosbuvir was a collaboration, and I am respected and lowered to get this acknowledgment,” Sofia said. “It is satisfying to see the huge great that originated from this work.”

Interminable contamination with the hepatitis C infection (HCV) is a noteworthy reason for liver cirrhosis and liver tumor. More than 170 million individuals around the world, including 4 million Americans, are constantly tainted with HCV, which was thought to be hopeless only 10 years prior. Today, with only 12 weeks of treatment with medication mixes that utilization Sofia’s medication, sofosbuvir (Sovaldi ) as the foundation of Harvoni , every one of those treated are cured. There remains no immunization to counteract disease with HCV.

Today, Sofia serves on the staff of the Baruch S. Blumberg Organization, the examination establishment of the Hepatitis B Establishment, and is Boss Logical Officer of Arbutus Biopharma. He and his group now are centered around building up a cure for incessant hepatitis B disease, and he is careful yet idealistic about their prospects.

“A cure for hepatitis B additionally will require a group approach,” Sofia said. “Hepatitis B is troublesome, however we and the Blumberg Organization have united a portion of the best researchers on the planet to accomplish this objective. We have put the hepatitis B infection in our line of sight, and we won’t give it a chance to escape.”

Timothy Square, Ph.D., president of the Hepatitis B Establishment and its Blumberg Organization and additionally the Dad Biotechnology Center, where both are headquartered, stated, “We are regarded and energized that our partner, Dr. Sofia, is getting this acknowledgment, which is so merited. The cure for hepatitis C is one of the best medicinal advances of my lifetime, and we have high trusts in a reprise execution with the hepatitis B infection.”

“The presentation of the Lasker-DeBakey Honor to Dr. Sofia additionally highlights the uncommon gauge of the researchers subsidiary with the Blumberg Foundation and the Biotech Center,” Square proceeded. “Eight men and ladies connected with the Biotech Center have found medications and analytic measures that are in human utilize today – and more advancements lie ahead.”

The Baruch S. Blumberg Organization was made by the Hepatitis B Establishment to bolster research to discover a cure for hepatitis B and related liver sicknesses. The hepatitis B infection, which constantly taints more than 240 million individuals around the world, causes cirrhosis and is the world’s driving reason for liver growth.

About the Baruch S. Blumberg Establishment: The Baruch S. Blumberg Organization is a free, not-for-profit explore initiate set up in 2003 by the Hepatitis B Establishment to lead disclosure research and sustain translational biotechnology in a domain helpful for association, coordinated effort and core interest. It was renamed in 2013 to respect Baruch S. Blumberg, who won the Nobel Prize for his revelation of the hepatitis B infection and helped to establish the Hepatitis B Establishment. To take in more, visit

Maribel Bauer

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *